There are currently 71 active clinical trials seeking participants for Metastatic Cancer research studies. The states with the highest number of trials for Metastatic Cancer participants are California, Ohio, Michigan and Illinois.
Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients
NCT05375994
Recruiting
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with adagrasib in patients with G12C Non-Small Cell Lung Cancer (NSCLC) who have been exposed to prior G12C inhibitor and experienced progressive disease.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/19/2023
Locations: UCSF Thoracic Oncology, San Francisco, California +7 locations
Conditions: Non Small Cell Lung Cancer, KRAS Activating Mutation, Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung, Malignant Neoplastic Disease
Register for Updates
Prospective Validation of a Points Score System Predicting 30-day Survival
NCT05100342
Recruiting
This is a one-stage single-arm phase II clinical trial designed to prospectively test the survival prediction tool as developed by Lee et al on patients referred to radiation oncology for palliative treatments. Survival prediction score based on objective data including laboratory values, attendance to emergency room, and primary cancer origin will be assigned to each patient at time of enrollment.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/29/2023
Locations: IU Health West, Avon, Indiana +4 locations
Conditions: Metastatic Cancer
Register for Updates
Advance Care Planning in the Emergency Department
NCT05209880
Recruiting
This is a two-armed, parallel-design, pre-/post-intervention assessment study. The investigators will conduct a randomized controlled trial for ED GOAL on a cohort of 120 older adults with serious illness to collect patient-centered outcomes and determine preliminary efficacy on increasing advance care planning engagement (self-reported and/or in the electronic medical record) one month after leaving the emergency department. The investigators will also conduct qualitative interviews with partic... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2023
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Congestive Heart Failure, Metastatic Cancer, Chronic Kidney Disease Requiring Chronic Dialysis, Chronic Obstructive Pulmonary Disease
Register for Updates
Study of TJ033721 in Subjects With Advanced or Metastatic Solid Tumors
NCT04900818
Recruiting
This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 in subjects with advanced or metastatic solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2023
Locations: Stern Center for Cancer Clinical Trials and Research, Orange, California +18 locations
Conditions: Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer, Gastroesophageal Junction Carcinoma, Esophageal Adenocarcinoma
Register for Updates
First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector
NCT04053283
Recruiting
To characterise the safety and tolerability of NG-641 in patients with metastatic or advanced epithelial tumours.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2023
Locations: University of Southern California (USC) - Norris Comprehensive Cancer Center, Los Angeles, California +5 locations
Conditions: Metastatic Cancer, Epithelial Tumor
Register for Updates
Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours
NCT05043714
Recruiting
This is a phase 1a/1b, multicentre, open-label, non-randomized study of NG-641 in combination with nivolumab (or standard of care PD-1 inhibition) in patients with metastatic or advanced epithelial tumours. The purpose is to characterize the safety and tolerability of NG-641 in combination with nivolumab in patients with metastatic or advanced epithelial tumours and to determine the recommended dose of NG-641 in combination with nivolumab for further development in patients with metastatic or a... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2023
Locations: Providence Medical Foundation, Fullerton, California +5 locations
Conditions: Metastatic Cancer, Epithelial Tumor
Register for Updates
Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy
NCT05574504
Recruiting
A nonrandomized phase II trial is proposed combining avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin as switch maintenance therapy for mUC following stable or responding disease on 4-6 cycles of first line platinum-based chemotherapy
Gender:
All
Ages:
18 years and above
Trial Updated:
05/08/2023
Locations: AdventHealth Cancer Institute, Orlando, Florida
Conditions: Metastatic Cancer, Urothelial Carcinoma
Register for Updates
Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
NCT04295863
Recruiting
A randomized research study of drugs nivolumab and pembrolizumab in patients with locally advanced or metastatic cancers. Based on data from earlier studies it appears that the drugs can be given less often then the currently approved schedule. This trial will compare drug levels from the blood from standard interval dosing levels versus taking the drugs less often.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/26/2023
Locations: University Of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois +1 locations
Conditions: Metastatic Cancer
Register for Updates
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
NCT04319757
Recruiting
ACE1702 (anti-HER2 oNK cells) is an off-the-shelf Natural Killer (NK) cell product that targets human HER2-expressing solid tumors. The ACE1702-001 phase I study aims to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ACE1702 in patients with advanced or metastatic HER2-expressing tumors, and to determine the phase Ib/II starting dose for ACE1702.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/07/2023
Locations: Northwestern Univeristy, Chicago, Illinois +2 locations
Conditions: Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor, HER2-positive Gastric Cancer, HER2-positive Metastatic Breast Cancer
Register for Updates
A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors
NCT04859777
Recruiting
This is a Phase 1/1b open-label, dose-escalation, and cohort expansion study with BID (tablet) oral dose of MPT-0118 in subjects with advanced or metastatic refractory solid tumors. The study will be conducted in 3 parts: Part A: MPT-0118 dose-escalation Part B: MPT-0118 dose-escalation in combination with pembrolizumab Part C: Cohort expansion of MPT-0118 in combination with pembrolizumab
Gender:
All
Ages:
18 years and above
Trial Updated:
09/15/2021
Locations: St. John's Cancer Center, Santa Monica, California +4 locations
Conditions: Solid Tumor, Adult, Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Refractory Cancer
Register for Updates
Metastatic Solid Cancer Clinical Trial
NCT04739618
Recruiting
This study seeks to estimate the potential efficacy of the study treatment, as well as the occurrence of adverse events.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/08/2021
Locations: Vincere Cancer Center, Scottsdale, Arizona
Conditions: Metastatic Cancer
Register for Updates